Analysts Set Expectations for Spring Bank Pharmaceuticals, Inc.’s FY2017 Earnings (SBPH)
Spring Bank Pharmaceuticals, Inc. (NASDAQ:SBPH) – Stock analysts at B. Riley issued their FY2017 earnings per share estimates for Spring Bank Pharmaceuticals in a research report issued to clients and investors on Monday. B. Riley analyst M. Kumar anticipates that the company will earn ($2.45) per share for the year. B. Riley has a “Buy” rating and a $30.00 price target on the stock. B. Riley also issued estimates for Spring Bank Pharmaceuticals’ Q4 2017 earnings at ($0.43) EPS, Q1 2018 earnings at ($0.46) EPS, Q2 2018 earnings at ($0.45) EPS, Q3 2018 earnings at ($0.44) EPS, Q4 2018 earnings at ($0.43) EPS, FY2018 earnings at ($1.70) EPS, FY2019 earnings at ($1.76) EPS, FY2020 earnings at ($1.98) EPS and FY2021 earnings at ($0.53) EPS.
Several other analysts also recently weighed in on the stock. Chardan Capital reiterated a “buy” rating on shares of Spring Bank Pharmaceuticals in a report on Monday. ValuEngine downgraded shares of Spring Bank Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, August 24th. Dawson James reiterated a “buy” rating on shares of Spring Bank Pharmaceuticals in a report on Monday, August 7th. Finally, Cantor Fitzgerald began coverage on shares of Spring Bank Pharmaceuticals in a report on Wednesday, July 19th. They issued an “overweight” rating and a $29.00 target price for the company. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $27.25.
COPYRIGHT VIOLATION NOTICE: This story was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another domain, it was illegally stolen and republished in violation of international trademark & copyright legislation. The original version of this story can be viewed at https://www.thecerbatgem.com/2017/11/08/analysts-set-expectations-for-spring-bank-pharmaceuticals-inc-s-fy2017-earnings-sbph.html.
Spring Bank Pharmaceuticals (NASDAQ SBPH) traded down $0.31 during trading on Wednesday, reaching $16.94. 1,723 shares of the company traded hands, compared to its average volume of 40,155. Spring Bank Pharmaceuticals has a 12-month low of $6.31 and a 12-month high of $17.94.
A number of institutional investors have recently bought and sold shares of the stock. C WorldWide Group Holding A S increased its holdings in Spring Bank Pharmaceuticals by 342.6% in the 3rd quarter. C WorldWide Group Holding A S now owns 111,200 shares of the company’s stock valued at $1,873,000 after purchasing an additional 86,077 shares during the last quarter. Morse Asset Management Inc increased its holdings in Spring Bank Pharmaceuticals by 94.7% in the 3rd quarter. Morse Asset Management Inc now owns 124,000 shares of the company’s stock valued at $2,004,000 after purchasing an additional 60,300 shares during the last quarter. Parsons Capital Management Inc. RI grew its stake in shares of Spring Bank Pharmaceuticals by 2.2% in the third quarter. Parsons Capital Management Inc. RI now owns 281,728 shares of the company’s stock worth $4,744,000 after acquiring an additional 6,000 shares in the last quarter. DAFNA Capital Management LLC acquired a new position in shares of Spring Bank Pharmaceuticals in the second quarter worth $217,000. Finally, Sectoral Asset Management Inc acquired a new position in shares of Spring Bank Pharmaceuticals in the second quarter worth $1,523,000. Hedge funds and other institutional investors own 28.04% of the company’s stock.
About Spring Bank Pharmaceuticals
Spring Bank Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of a class of therapeutics using its small molecule nucleic acid hybrid (SMNH) chemistry platform. The Company is developing its SMNH product, SB 9200, for the treatment of viral diseases.
Receive News & Stock Ratings for Spring Bank Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spring Bank Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.